Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News For Jul 30, 2019

by Zacks Equity Research

Companies in the News Are: MYL, SNY, CTB, MCY.

Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer

by Zacks Equity Research

Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.

Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan

by Zacks Equity Research

Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.

Mylan (MYL) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Mylan (MYL) delivered earnings and revenue surprises of 8.42% and 0.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong

by Zacks Equity Research

Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

Amneal (AMRX) Down on Guidance Update & Restructuring Plan

by Zacks Equity Research

Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.

Mylan (MYL) Down 18.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Teva Settles With Oklahoma, Shares Fall Following Downgrade

by Zacks Equity Research

Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.

Options Traders Expect Huge Moves in Mylan (MYL) Stock

by Zacks Equity Research

Investors need to pay close attention to Mylan (MYL) stock based on the movements in the options market lately.

Amgen (AMGN) Offers to Acquire Drug Discovery Platform

by Zacks Equity Research

Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

AbbVie Settles Humira Litigation With Boehringer Ingelheim

by Zacks Equity Research

AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

Kinjel Shah headshot

Generic Drugmakers Face Antitrust Suit Alleging Price Fixing

by Kinjel Shah

Shares of generic drugmakers decline on allegations of price fixing by 44 states.

Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates

by Zacks Equity Research

Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.

Company News For May 8, 2019

by Zacks Equity Research

Companies In The News Are: MYL,AIG,ARMK,ATKR

Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

Mylan (MYL) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Mylan (MYL) delivered earnings and revenue surprises of 3.80% and -7.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.

Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall

by Zacks Equity Research

Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

    Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1

    by Zacks Equity Research

    Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.

    Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses

    by Zacks Equity Research

    Glaxo (GSK) beats earnings and sales estimates for the first quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

    Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure

    by Zacks Equity Research

    Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.

    Earnings Preview: Mylan (MYL) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    Mylan (MYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.